Provided by Tiger Trade Technology Pte. Ltd.

Lipocine

8.49
+0.77009.97%
Post-market: 8.490.00000.00%16:10 EST
Volume:120.72K
Turnover:1.02M
Market Cap:47.14M
PE:-8.32
High:8.91
Open:7.84
Low:7.84
Close:7.72
52wk High:12.37
52wk Low:2.52
Shares:5.55M
Float Shares:5.39M
Volume Ratio:1.61
T/O Rate:2.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0204
EPS(LYR):-0.0016
ROE:-32.92%
ROA:-21.45%
PB:3.33
PE(LYR):-5,224.62

Loading ...

Company Profile

Company Name:
Lipocine
Exchange:
NASDAQ
Establishment Date:
1997
Employees:
16
Office Location:
675 Arapeen Drive,Suite 202,Salt Lake City,Utah,United States
Zip Code:
84108
Fax:
801 994 7388
Introduction:
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.

Directors

Name
Position
Mahesh V. Patel
President, Chief Executive Officer and Director
Spyros Papapetropoulos
Lead Independent Director and Chairman of the Board
Jill M. Jene
Director
John W. Higuchi
Director
Richard Dana Ono
Director

Shareholders

Name
Position
Mahesh V. Patel
President, Chief Executive Officer and Director
Nachiappan Chidambaram
Senior Vice President, Research and Development
Krista Fogarty
Principal Accounting Officer and Corporate Controller